Skip to main content
. Author manuscript; available in PMC: 2020 Oct 1.
Published in final edited form as: Alcohol Clin Exp Res. 2019 Aug 21;43(10):2167–2178. doi: 10.1111/acer.14165

Figure 4.

Figure 4.

Effects of administration of the NOP receptor agonist AT-202 and the antagonist SB-612111 on locomotor activity. Mice received injection (ip) of AT-202 (0, 3 mg/kg) or SB-612111 (0, 30 mg/kg) 30 min prior to 30-min locomotor activity assessment in the open field test conducted under familiarity conditions. (A & B) AT-202 treatment did not affect horizontal activity but (C & D) reduced vertical activity. (E & F) SB-612111 treatment reduced horizontal activity, whereas (G & H) vertical activity was not significantly altered. Data are expressed as mean (± SEM) 5-min fractions and total ambulatory counts (horizontal activity) and as mean (± SEM) 5-min fractions and total vertical counts (vertical activity) of N=8 mice per group. * p<0.05 difference from vehicle groups (0 mg/kg). +p<0.05, ++p<0.01 difference from vehicle groups (0 mg/kg). For detailed statistics, see “Results”.